Inhibitory effect of the water-soluble retinoid X receptor partial agonist CAt-PMN on allergic conjunctivitis-like responses in mice
Experimental Eye Research · 2026-09 · 270 · 111131
DOI: 10.1016/j.exer.2026.111131 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Eye Research, 2026-09. Verfasst von Atsushi Ogura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Inflammatory Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Tsushima-naka 1-1-1, …. Hauptthemen laut MEDLINE: Conjunctivitis, Allergic, Retinoid X Receptors. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Allergic conjunctivitis (AC) is an immune-mediated inflammatory disease of the conjunctiva characterized by ocular itching, hyperaemia, and edema, and inflammatory cell infiltration. Though topical glucocorticoids (steroidal anti-inflammatory drugs) are effective for a broad range of signs and symptoms of ocular inflammation, their use is limited by potential adverse effects, including elevated intraocular pressure (IOP). Therefore, steroidal sparing-therapeutic approachs for AC are needed. Here we report a therapeutic effect of CAt-PMN, the highly water-soluble retinoid X receptor (RXR) partial agonist, in a mouse model of AC. ICR mice were sensitized by intraperitoneal injection of ovalbumin (OVA) on days 0 and 5, followed by topical OVA challenge once a daily from day 14 to day 28. Betamethasone (0.1% w/v) or CAt-PMN (0.0035 or 0.035% w/v) was instilled into both eyes before each topical OVA challende. Repeated topical administration of CAt-PMN suppressed eye scratching behavior, allergic-like clinical symptoms, and eosinophils infiltration of into tears in a dose dependent manner. In a separate repeated-dose IOP study using C57BL/6 mice, topical dexamethasone at 1 μM induced a marked IOP elevation, whereas topical CAt-PMN at 1 μM did not under the conditions tested. These findings suggest that CAt-PMN may be a promising steroid-sparing therapeutic candidate for AC, although further studies using the same mouse strain and detailed ocular pharmacokinetic and safety evaluations are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Inflammatory Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Tsushima-naka 1-1-1, Kita-ku, Okayama, 700-8530, Japan.
- Laboratory of Bioorganic and Medicinal Chemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Tsushima-naka 1-1-1, Kita-ku, Okayama, 700-8530, Japan.
- Department of Ophthalmology, Ocular Surface Center, Baylor College of Medicine, Houston, TX, United States.
- Laboratory of Inflammatory Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Tsushima-naka 1-1-1, Kita-ku, Okayama, 700-8530, Japan. Electronic address: sugimoto@okayam…
Zitieren
APA
Ogura, A., Takamura, Y., Takimoto, Y., Hino, Y., Kakuta, H., Alam, J., Pflugfelder, S. C., & Sugimoto, Y. (2026). Inhibitory effect of the water-soluble retinoid X receptor partial agonist CAt-PMN on allergic conjunctivitis-like responses in mice. Experimental Eye Research, 270, 111131. https://doi.org/10.1016/j.exer.2026.111131
Vancouver
Ogura A, Takamura Y, Takimoto Y, Hino Y, Kakuta H, Alam J, et al. Inhibitory effect of the water-soluble retinoid X receptor partial agonist CAt-PMN on allergic conjunctivitis-like responses in mice. Experimental Eye Research. 2026;270:111131. doi:10.1016/j.exer.2026.111131
BibTeX
@article{Ogura2026,
author = {Ogura, Atsushi and Takamura, Yuta and Takimoto, Yuka and Hino, Yuta and Kakuta, Hiroki and Alam, Jehan and Pflugfelder, Stephen C and Sugimoto, Yukio},
title = {Inhibitory effect of the water-soluble retinoid X receptor partial agonist CAt-PMN on allergic conjunctivitis-like responses in mice},
journal = {Experimental Eye Research},
year = {2026},
volume = {270},
pages = {111131},
doi = {10.1016/j.exer.2026.111131}
}
EUVIMED